Cardiovascular disease in systemic lupus erythematosus: The role of traditional and lupus related risk factors

Current Cardiology Reviews

Volumn 4, Issue 2, 2008, Pages 116-122

  Zeller, Carlos Borelli ^a   Appenzeller, Simone ^a,b,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Cardiovascular disease; Systemic lupus erythematosus

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; AUTOANTIBODY; AUTOANTIGEN; C REACTIVE PROTEIN; CORTICOSTEROID; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; PREDNISONE;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 48249096012     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308784245775     Document Type: Review

References (102)

1. Esdaile JM, Abrahamowicz M, Grodzicky T, el al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythernatosus. Arthritis Rheum 2001; 44: 23331-7.
2. Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2005; 2: 423-30.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
4. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: 2-10.
5. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
7. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006; 5: 331-7.
8. Mombouli J, Vanhouette PM. Endothelial dysfanction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
9. Kbarbanda R, Deanfield J. Functions of the healthy endothelium. Cor Art Dis 2001; 12: 485-491.
10. Abusamieh M, Ash J. Atherosclerosis and systemic lupus erythematosus. Cardiol Rev 2004; 12: 267-75.
11. Agewall S. Is impaired flow-mediated dilation of the brachial artery a cardiovascular risk factor? Curr Vase Pharmacol 2003; 1: 107-9.
12. Bacon PA. Endothelial cell dysfunction in systemic vasculitis: New developments and therapeutic prospects. Curr Opin Rheumatol 2005; 17: 49-55.
13. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
14. Bacon PA. Endothelial cell dysfunction in systemic vasculitis: New developments and therapeutic prospects. Curr Opin Rheurnatol 2005; 17: 49-55.
15. Lima DS, Sato El, Lima VC, Miranda F, Hatta FM. Brachial endothelial function is impaired in patients with systemic lupus crythematosus. J Rheumatol 2002; 29: 292-7.
16. Constans J, Dupuy R, Blann AD, et al. Anti-endothelial cell autoantibodics and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 2003; 30: 1963-6.
17. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-90.
18. Antoni P, Edward TH, Lawrence C. A proatherogenic role for Creactive protein in vivo. Curr Opin Lipidol 2005; 16: 512-7.
19. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7.
20. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of Creactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-60.
21. Zampieri S, Iaccarino L, Ghirardello A, et al. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci 2005 Jun; 1051: 351-61.
22. Nicolo D, Monestier M. Antiphospholipid antibodies and atherosclerosis. Clin Immunol 2004; 112: 183-189.
23. Shoenfeld Y, Sherer Y, Haratz D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001; 22: 293-295.
24. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.
25. Xu Q, Wick G. The role of heat shock proteins in protection and pathophysiology of the arterial wall. Mol Med Today 1996; 2: 372-379.
26. Sorelle R. Blood containing high levels of antibodies to heat shock protein 65 (hsp65) were found to be at increased risk of subsequent cardiovascular events. Circulation 2002; 106: 9052-9058.
27. Xu Q, Kiechl S, Mayr M, et al. Association of serum antibodies to heatshock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999; 100: 1169-1174.
28. Xu Q, Kiechl S, Mayr M, et al. Association of serum antibodies to heatshock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-259.
29. Shoenfeld Y, Sherer Y, George J, Harats D. Autoantibodies associated with atherosclerosis. Ann Med 2000; 32: 37-40.
30. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991; 90: 119-126.
31. Stemme S, Faber B, Holm J, et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density, lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-3897.
32. Frostgard J, Huang YH, Ronnelid J, Schaffer L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997; 17: 963-968.
33. Wu R, Lefvert AK. Autoantibodies against oxidized low-density lipoproteins (oxLDL): characterization of antibody isotope, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995; 102: 174-180.
34. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early onset of peripheral vascular disease have high levels of autoantibodies against oxidized low-density lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 441-445.
35. George J, Harats D, Gilburd B, Afek A, et al. Immunolocalization of 2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999; 99: 2227-2230.
36. Hansson GK. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N Eng J Med 2005; 352: 1685-1695.
37. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis. N Engl J Med 2000; 343: 522-529.
38. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med 1975; 58: 243-264.
39. Urowitz MB, Bookman AAM, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
40. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus crythematosus. Am J Med 1992; 93: 513-519.
41. Manzi S, Mcilahn EN, Rairice JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus crythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
42. Salmon J, Roman M. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 2001; 13: 341-344.
43. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005 June; 257(6): 485-95
44. Mitsias P, Levine SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology 1994; 44: 385-93.
45. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-93.
46. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
47. Wolak T, Todosoui E, Szendro G, et al. Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J Rheumatol 2004; 31: 909-14.
48. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004 Aug; 3: 423-53
49. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.
50. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987; 14: 223-6.
51. Badui E, Garcia-Rubi D, Robles E, et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985; 36: 431-41.
52. Bruce IN, Gladman DD, Ibanez D, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus: II. Predictive factors for perfusion abnormalities. J Rheumatol 2003; 30: 288-91.
53. Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A. Myocardial perfusion cintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1066-70.
54. Hosenpud JD, Montanaro A, Hart MV, et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984; 77: 286-92.
55. Gazarian M, Feldman BM, Benson LN, Gilday DL, Laxer RM, Silverman ED. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr 1998; 132: 109-16.
56. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
57. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
58. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-15.
59. Manger K, Kusus M, Forster C, et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62: 846-50.
60. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-93.
61. Font J, Ramos-Casals M, Cervera R, et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM 2001; 94: 19-26.
62. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999; 92: 211-8.
63. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset; black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33: 37-48.
64. Nossent JC. Course and prognostic value of systemic lupus erythematosus disease activity index in black Caribbean patients. Semin Arthritis Rheum 1993; 23: 16-21.
65. Jacobsen S, Petersen J, Ullman S, et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand. J Rheumatol 1999; 28: 75-80.
66. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.
67. Toloza SM, Uribe AG, McGwin G, et al. Systemic 1upus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-57.
68. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-7.
69. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
70. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
71. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-15.
72. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-93.
73. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159-67.
74. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999; 26: 2363-8.
75. Lee AB, Godfrey T, Rowley KG, et al. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 2006; 36: 237-43.
76. Roman W, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406
77. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151-9.
78. Kitagawa Y, Gotoh F, Koto A, Okayasu H. Stroke in systemic lupus erythematosus. Stroke 1990; 21:1533-9.
79. Manger K, Kusus M, Forster C, et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62: 846-50.
80. Font J, Ramos-Casals M, Cervera R, et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM 2001; 94: 19-26.
81. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.
82. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
83. Manger K, Kusus M, Forster C, et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62: 846-50.
84. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-93.
85. Rahman P, Gladman DD, Urowitz MB. Premature coronary artery disease in systemic lupus erythematosus in the absence of corticosteroid use. J Rheumatol 2000; 27: 1323-5.
86. George J, Harats D, Gilburd B, et al. Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of Immoral immunity in enhanced atherogenesis. Lupus 1999; 8: 220-226.
87. Doria A, Shoenfeld Y, Wu R. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-1077.
88. Hayem G, Nicaise-Roland P, Palazzo E, et al. Anti-oxidized low-densitylipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001; 6-351.
89. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 887-1893.
90. Emeson EE, Shen ML, Bell CG, et al. Inhibition of atherosclerosis in CD4 T-cell-depleted and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol 1996; 149: 675-685.
91. Vaarala O, Manttari V, Mannienen, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-27.
92. Sherer Y, Shemesh J, Tenenbaum A, et al. Coronary calcium and anti-cardiolipin antibody are elevated in patients with typical chest pain. Am J Cardiol 2000; 86:1306-1311.
93. Sherer Y, tenebaum A, Blank M, et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, β-2-glycoprotein-I, and oxidized-LDL antibodies. Cardiology 2001; 95: 20-24.
94. Ames PR, Margarita A, Delgado J, et al. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness ofcarotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 208-214.
95. Medina G, Casaos LJ, Jara J, et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 42: 607-610.
96. Vlachoyiannpoulos PG, Kanellopoulos PG, Ioannidis JP, et al. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 2003; 42: 645-651.
97. Xu Q, Dietrich H, Steiner HJ, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb, 1992; 12: 789-799.
98. Sun S, Shiau Y, Tsai S, et al. The role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology 2001; 40: 1106-1111.
99. Roman M, Salmon J, Sobel R, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001; 87: 663-666.
100. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
101. Ridker P, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reaetive protein. Circulation 1999; 100: 230-235.
102. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780-5.